type 2 diabetes medicine
0 conceptsDocumented exceptionOnce-weekly tirzepatide injection for improving blood glucose control in adults and children 10 and older with type 2 diabetes.
A tighter look at the products that matter most to Eli Lilly, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 0 structured disruption concepts across the current product set.
type 2 diabetes medicine
0 conceptsDocumented exceptionOnce-weekly tirzepatide injection for improving blood glucose control in adults and children 10 and older with type 2 diabetes.
obesity medicine
0 conceptsDocumented exceptionOnce-weekly tirzepatide injection for chronic weight management in adults with obesity or overweight with weight-related conditions, with an additional U.S. approval for obstructive sleep apnea in adults with obesity.
Paper trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Eli Lilly and Company · annual report
Primary source for company business description, 2025 revenue, 2025 net income, product concentration, and tirzepatide revenue disclosures.
Reviewed 2026-03-24
Eli Lilly and Company · investor relations
Supports current commercial momentum narrative for Zepbound and Mounjaro and ongoing manufacturing expansion context.
Reviewed 2026-03-24
CompaniesMarketCap · market data
Used for current market cap estimate and approximate global rank reviewed on March 24, 2026.
Reviewed 2026-03-24
MacroTrends · market data
Used for point-in-time PE ratio reference in March 2026.
Reviewed 2026-03-24
Eli Lilly and Company · product page
Used for Mounjaro indication, dosing form, and prescription-product framing.
Reviewed 2026-03-24
Eli Lilly and Company · product page
Used for Zepbound indication and prescription-product framing.
Reviewed 2026-03-24